ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "Biologicals"

  • Abstract Number: L07 • ACR Convergence 2022

    Telitacicept, a Human Recombinant Fusion Protein Targeting B Lymphocyte Stimulator (BlyS) and a Proliferation-Inducing Ligand (APRIL), in Systemic Lupus Erythematosus (SLE): Results of a Phase 3 Study

    Di Wu1, Jing Li1, Dong Xu1, Li Wang1, Jianmin Fang2, Dan Ross3 and Fengchun Zhang4, 1Department of Rheumatology and Clinical Immunology Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China, Beijing, China, 2Shanghai Tongji Hospital, Tongji University, Shanghai 200065, China School of Life Science and Technology, Tongji University, Shanghai 200092, China, Shanghai, China, 3RemeGen Co., San Diego, CA, 4Department of Rheumatology and Clinical Immunology Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China; Key Laboratory of Rheumatology & Clinical Immunology, Ministry of Education, Beijing, China, Beijing, China

    Background/Purpose: Telitacicept is a novel recombinant fusion protein constructed with the extracellular domain of the human transmembrane activator and calcium modulator and cyclophilin ligand interactor…
  • Abstract Number: L12 • ACR Convergence 2022

    First Line Treatment Using Recombinant IL-1Receptor Antagonist in New Onset Systemic Juvenile Idiopathic Arthritis Is an Effective Treatment Strategy, Irrespective of HLA DRB1 Background

    Remco Erkens1, Rashmi Sinha2, Alex Pickering3, Grant Schulert4, Alexei Grom4, Lars van der Veken1, Hanneke van Deutekom1, Jorg Calis1, Jorg van Loosdregt5 and Sebastiaan Vastert1, 1University Medical Center Utrecht, Utrecht, Netherlands, 2Systemic JIA Foundation, Cincinnati, OH, 3Systemic JIA Foundation, San Francisso, CA, 4Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 5University Medical Center Utrecht, Wilhelmina Children's Hospital, Zeist, Netherlands

    Background/Purpose: Systemic Juvenile Idiopathic Arthritis (sJIA) is a severe subtype of JIA. Recently, interstitial lung disease (SJIA-LD) has been reported as a severe complication of…
  • Abstract Number: 0133 • ACR Convergence 2022

    Retention Rate of Targeted Therapies in Erdheim-Chester Disease

    Corrado Campochiaro1, alessandro tomelleri1, Francesco Pegoraro2, Giovanni Galardi3, Nicola Farina4, Martina Mazzariol5, Francesco Catamerò6, Giacomo De Luca4, Giulio Cavalli4, Augusto Vaglio7 and Lorenzo Dagna8, 1IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University, Milano, Italy, 2Department of Health Sciences, University of Florence, Firenze, Italy, 3Department of Health Sciences, University of Florence, Florence, Italy, 4IRCCS San Raffaele Hospital - Vita-Salute San Raffaele University, Milano, Italy, 5University of Turin, Torino, Italy, 6Vita-Salute San Raffaele University, Milano, Italy, 7Azienda Ospedaliero Universitaria Meyer, Parna, Italy, 8IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, Milano, Italy

    Background/Purpose: Erdheim-Chester disease (ECD) is a rare non-Langerhans histiocytosis with a broad clinical spectrum. The therapeutic landscape of ECD has remarkably changed over the last…
  • Abstract Number: 0312 • ACR Convergence 2022

    Dose-dependent Suppression of T Cell-Dependent Antibody Response in Healthy Volunteers by KPL-404, an Anti-CD40 Monoclonal Antibody, Supports Phase 2 Study in Patients with Rheumatoid Arthritis

    Lara Pupim1, Gerd Burmester2, Fang Fang1, Alan Kivitz3, Moses Njenga1, Costantino Pitzalis4, Jay Chatfield1, Anastassia Papandrikopoulou1, Manoj Samant1, Steve Schmitz1, Madeline Spiers1, Eben Tessari1, John Ziemniak1 and John F. Paolini5, 1Kiniksa, Lexington, MA, 2Charité University Medicine Berlin, Berlin, Germany, 3Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA, 4Queen Mary University of London, London, United Kingdom, 5Kiniksa Pharmaceuticals, Lexington, MA

    Background/Purpose: An unmet need remains in patients with failure and/or inadequate response (IR) to biological disease-modifying antirheumatic drugs (bDMARD-IR) and/or Janus kinase inhibitors (JAKi-IR). The…
  • Abstract Number: 0422 • ACR Convergence 2022

    Efficacy and Safety of Secukinumab in the Treatment of Axial Spondyloarthritis: Real-Life Data from TURKBIO Cohort

    Semih Gulle1, Ali Karakas1, Gercek Can2, Soner Senel3, Sedat Capar4, Huseyin ediz dalkilic5, Servet Akar6, Suleyman Serdar Koca7, Abdurrahman Tufan8, Ayten Yazici9, Sema Yilmaz10, Nevsun Inanc11, Merih Birlik1, Dilek Solmaz12, Ayse Cefle9, Berna Goker13, Servet Yolbas14, Niels Steen Krough15, Neslihan Yilmaz16, Sukran Erten17, Cemal Bes18, Ozgul Soysal19, Mehmet Akif Ozturk13, Seminur Haznedaroglu13, Sule Yavuz16, Haner Direskeneli20, Fatoş Onen21 and Ismail Sari22, 1Dokuz Eylul University School of Medicine Division of Rheumatology, Izmir, Turkey, 2Dokuz Eylul University School of Medicine Division of Rheumatology, Istanbul, Turkey, 3Erciyes University School of Medicine Division of Rheumatology, Kayseri, Turkey, 4Dokuz Eylul University Faculty of Science Department of Statistics, Izmir, Turkey, 5Uludag University School of Medicine Division of Rheumatology, Bursa, Turkey, 6Izmir Katip Celebi University School of Medicine, Izmir, Turkey, 7Firat University School of Medicine Division of Rheumatology, Elazıg, Turkey, 8Gazi University Medical Faculty Hospital, Istanbul, Turkey, 9Kocaeli University School of Medicine Division of Rheumatology, Kocaeli, Turkey, 10Selcuk University School of Medicine Division of Rheumatology, Konya, Turkey, 11Marmara University School of Medicine, Division of Rheumatology, Istanbul, Turkey, 12Kâtip Celebi University School of Medicine Division of Rheumatology, Izmir, Turkey, 13Gazi University School of Medicine Division of Rheumatology, Ankara, Turkey, 14Inonu University School of Medicine Division of Rheumatology, Malatya, Turkey, 15Zitelab Aps, Kopenhag, Denmark, 16Demiroglu Bilim University School of Medicine Division of Rheumatology, Istanbul, Turkey, 17Yildirim Beyazit University School of Medicine Division of Rheumatology, Ankara, Turkey, 18Basaksehir Cam and Sakura ospital, Division of Rheumatology, Istanbul, Turkey, 19Celal Bayar University, School of Medicine Division of Rheumatology, Manisa, Turkey, 20Marmara University School of Medicine Division of Rheumatology, Istanbul, Turkey, 21Dokuz Eylul University, Faculty of Medicine, Rheumatology, İzmir, Turkey, 22Dokuz Eylul University School of Medicine Division of Rheumatology, İzmir, Turkey

    Background/Purpose: In this study, we aimed to evaluate the results of secukinumab treatment in patients with Axial Spondyloarthritis (AxSpA) who were enrolled in the TURKBIO…
  • Abstract Number: 0747 • ACR Convergence 2022

    Methotrexate and Hydroxychloroquine Used as Single Agent May Diminish Breakthrough Infection After COVID-19 Vaccination

    Haihui Wang1 and Andras Perl2, 1Upstate Medical University, Fayetteville, NY, 2SUNY, Syracuse, NY

    Background/Purpose: Immunosuppressive medications generally predispose patients to greater risk of serious complications upon COVID-19 infection. This study was initiated to assess whether individual drugs may…
  • Abstract Number: 0826 • ACR Convergence 2022

    Treatment Pattern and Changes in Oral Glucocorticoid Dose After Tocilizumab Treatment in Patients with Adult Still’s Disease: An Analysis of a Japanese Claims Database

    Yuko Kaneko1, Hideto Kameda2, Kei Ikeda3, Katsuhisa Yamashita4, Ryoto Ozaki5 and Yoshiya Tanaka6, 1Keio University School of Medicine, Tokyo, Japan, 2Toho University, Tokyo, Japan, 3Chiba University Hospital, Chiba, Japan, 4Chugai Pharmaceutical Co., Ltd., Chuo-ku, Tokyo, Japan, 5Chugai Pharmaceutical Co. Ltd., Tokyo, Japan, 6University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan

    Background/Purpose: Adult Still's disease (ASD), including adult-onset Still's disease and carry-over systemic juvenile idiopathic arthritis (sJIA), is treated with glucocorticoids (GC) with or without immunosuppressive…
  • Abstract Number: 1001 • ACR Convergence 2022

    Effect of Atacicept on Renal Function in Patients with Systemic Lupus Erythematosus (SLE)

    David Isenberg1, Celia Lin2, Amy Kao3, Aida Aydemir4 and Caroline Gordon5, 1University College London, London, United Kingdom, 2Vera Therapeutics, Inc, Burlingame, CA, 3EMD Serono, Billerica, MA, 4EMD Serono Research & Development Institute, Inc, Billerica, MA, 5Rheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom

    Background/Purpose: Atacicept is a fusion protein that blocks B-lymphocyte stimulator and a proliferation-inducing ligand, which are increased in patients with SLE. APRIL-SLE was a double-blind,…
  • Abstract Number: 1286 • ACR Convergence 2022

    Increasing Biosimilar Uptake in the Rheumatology Clinics Within a Large Academic Medical Center

    Joad Eseddi1, DeAnne Carmichael2, Shannon Wishin3 and Puneet Bajaj2, 1UT Southwestern School of Medicine, Dallas, TX, 2UT Southwestern Medical Center, Dallas, TX, 3UT Southwestern Medical Centre, Dallas, TX

    Background/Purpose: Biological drugs have revolutionized the treatment of rheumatic diseases. However, increasing the use of biologics over the past few years has directly contributed towards…
  • Abstract Number: 1435 • ACR Convergence 2022

    Effectiveness of Combination Therapy with Tocilizumab and Low-Dose Prednisolone as an Induction Therapy in Biologics-Naïve Patients with Rheumatoid Arthritis: A Prospective, Randomized, Controlled, Open-Label, Multicenter Study

    Kazuhiro Yokota1, Hayato Nagasawa2, Yuji Akiyama3 and Toshihide Mimura4, 1Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Iruma Saitama, 2Nagasawa Clinic, Kawagoe, Japan, 3Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Iruma Saitama, Japan, 4Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan

    Background/Purpose: Efficacy and safety of tocilizumab (TCZ) in the treatment of rheumatoid arthritis (RA) has demonstrated in randomized controlled trials. However, the clinical response to…
  • Abstract Number: 1834 • ACR Convergence 2022

    Canakinumab Treatment in Familial Mediterranean Fever Patients with Colchicine Resistance: A Single-center Study

    Ibrahim Durucan1, Ali Yagiz Ayla2, Helin Idil Besiroglu1, Arif Alkan1, Oguzhan Selvi1, Huri Ozdogan1 and Serdal Ugurlu2, 1Istanbul University-Cerrahpaşa Medical Faculty, Istanbul, Turkey, 2Istanbul University-Cerrahpaşa, Istanbul, Turkey

    Background/Purpose: Recurrent fever and serositis are the hallmarks of Familial Mediterranean fever (FMF). Colchicine is known for yielding high success in disease control by obviating…
  • Abstract Number: 2112 • ACR Convergence 2022

    Stringent Disease Activity Control at 2 Years Across Psoriatic Arthritis Domains Irrespective of Baseline Characteristics in Patients Treated with Guselkumab: Post Hoc Analysis of a Phase 3, Randomized, Double-blind, Placebo-controlled Study

    Christopher Ritchlin1, Philip J Mease2, Wolf-Henning Boehncke3, John Tesser4, Soumya Chakravarty5, Emmanouil Rampakakis6, May Shawi7, Elena Schiopu8, Joseph Merola9, Iain B McInnes10 and Atul Deodhar11, 1Allergy, Immunology and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY, 2Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, 3Deptartment of Dermatology, Geneva University Hospitals, University of Geneva, Geneva, Switzerland, 4Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, 5Janssen Scientific Affairs, LLC; Drexel University College of Medicine, Villanova, PA, 6McGill University, Department of Pediatrics and JSS Medical Research, Montréal, QC, Canada, 7Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, 8Michigan Medicine Rheumatology Clinic – Taubman Center, Ann Arbor, MI, 9Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 10Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom, 11Oregon Health & Science University, Portland, OR, USA, Portland, OR

    Background/Purpose: Guselkumab (GUS) is associated with robust and sustained improvement in PsA signs and symptoms in subgroups of patients (pts) pooled from the phase 3…
  • Abstract Number: 2200 • ACR Convergence 2022

    Reliability of Medication Information Derived from EHR Data Compared to Insurance Claims: An Analysis of Biologic Medications in RISE and Medicare

    Rahaf Baker1, Jing Li2, Rachael Stovall3, Jeffrey Curtis4, Fenglong Xie5, Jinoos Yazdany6 and Gabriela Schmajuk7, 1Alameda Highland Internal Medicine Residency, Oakland, CA, 2University of California, San Francisco, San Francisco, CA, 3University of California San Francisco, San Francisco, CA, 4University of Alabama at Birmingham, Hoover, AL, 5University of Alabama at Birmingham, Birmingham, AL, 6UCSF, San Francisco, CA, 7UCSF / SFVA, San Francisco, CA

    Background/Purpose: Health services studies increasingly rely on Electronic Health Record (EHR) data to capture medication use. However, the reliability of medication information derived from EHR…
  • Abstract Number: 0138 • ACR Convergence 2022

    Patients with Familial Mediterranean Fever (FMF) Under Canakinumab Treatment – Long-term Efficacy and Safety Interim Data of the RELIANCE Registry

    Joerg Henes1, Jasmin B. Kuemmerle-Deschner2, Tobias Krickau3, Tilmann Kallinich4, Frank Dressler5, Gerd Horneff6, Florian Meier7, Ivan Foeldvari8, Frank Weller-Heinemann9, Birgit Kortus-Goetze10, Markus Hufnagel11, Juergen Rech12, Prasad T. Oommen13, Julia Weber-Arden14 and Norbert Blank15, 1Center for Interdisciplinary Clinical Immunology, Rheumatology and Auto-inflammatory Diseases (INDIRA), University Hospital Tübingen, Tübingen, Germany, 2Department of Pediatrics, Division of Pediatric Rheumatology, University Hospital Tübingen, Tübingen, Germany, 3Friedrich-Alexander Universität Erlangen-Nürnberg (FAU), Pediatrics, Erlangen, Germany, 4Charité - Universitätsmedizin Berlin, Nuremberg, Germany, 5Division of Pediatric Pneumology, Allergology and Neonatology, Hannover Medical School, Hannover, Germany, 6Pediatrics, Asklepios Klinik Sankt Augustin GmbH, Sankt Augustin, Germany, 7Division of Rheumatology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany, and Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP, Frankfurt, Germany, 8Hamburger Zentrum für Kinder- und Jugendrheumatologie, Hamburg, Germany, 9Klinikum Bremen-Mitte, Prof. Hess Kinderklinik, Bremen, Germany, 10Division of Nephrology, University of Marburg, Marburg, Germany, 11Division of Pediatric Infectious Diseases and Rheumatology, Department of Pediatrics and Adolescent Medicine, University Hospital Medical Center Freiburg, Medical Faculty, University of Freiburg, Freiburg, Germany, 12University Clinic Erlangen, Erlangen, Germany, 13Clinic of Pediatric Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany, 14Novartis Pharma GmbH, Nuernberg, Germany, 15Rheumatology, University Hospital Heidelberg, Heidelberg, Germany

    Background/Purpose: Familial Mediterranean fever (FMF) is a chronic disease characterized by recurrent episodes of fever and serositis, with a risk of severe complications (e. g.…
  • Abstract Number: 0313 • ACR Convergence 2022

    Olokizumab Improves Patient Reported Outcomes in Moderate to Severely Active Rheumatoid Arthritis Patients Inadequately Controlled by Methotrexate (MTX-IR): Results from the Phase III Randomized Controlled Trial

    Vibeke Strand1, Evgeny Nasonov2, Tatiana Lisitsyna2, Alexander Lila2, Sofia Kuzkina3, Mikhail Samsonov4 and Eugen Feist5, 1Stanford University School of Medicine, Stanford, CA, 2V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia, 3R-Pharm, Moscow, Russia, 4R-Pharm JSC, Moscow, Russia, 5Helios Clinic Vogelsang-Gommern, cooperation partner of the Otto von Guericke University Magdeburg, Magdeburg, Germany

    Background/Purpose: Olokizumab (OKZ) is an interleukin-6-inhibitor for treatment of Rheumatoid Arthritis (RA). In these analyses, we present patient reported outcomes (PROs) reported by MTX-IR patients…
  • 1
  • 2
  • 3
  • …
  • 30
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences